Laurine Verset
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laurine Verset has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Anne Trelcat
Department of Cardiology, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), 7000 Mons, Belgium
2 shared publications - Arnaud Lemmers
Erasmus Hospital, Brussels, Belgium
2 shared publications - Christelle Bouchart
Department of Radiation Oncology, HUB Institut Jules Bordet, Université Libre de Bruxelles, Rue Meylenmeersch 90, 1070 Brussels, Belgium; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
2 shared publications - Fabrice Journe
Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Avenue du Champ de Mars, 8, B7000 Mons, Belgium
2 shared publications - Jacques Devière
Hospital Erasme, Bruxelles, Belgium
2 shared publications - Jean-Christophe Noël
Department of Pathology, Hôpital Universitaire de Bruxelles (H.U.B.)/Bordet-Erasme, Université Libre de Bruxelles (ULB), Rue Meylemeersch 90, 1070 Brussels, Belgium
2 shared publications
Latest Publications
- Open Access
Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer
Purpose Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, largely due to chemoresistance arising from prominent cellular heterogeneity and a complex tumor microenvironment. Given this challenge, understanding the mechanisms of driving chemoresistance is essential for guiding our chemotherapeutic choice. Emerging evidence suggests that methylglyoxal (MG), a reactive glycolytic byproduct, may play a role in modulating tumor behavior and therapy response, offering a novel angle for patient stratification. Our recent study indicates that the accumulation of MG in PDAC cells leads to MG-induced cellular stress associated with gemcitabine (GEM) resistance. The primary objective of this study was to identify a predictive transcriptomic signature associated with MG stress in PDAC and compare it to the recently reported GemPred signature. Patients and methods MG stress classification was applied to the Puleo et al. cohort (n=309), enabling differential gene expression analysis and the development of a prognostic 16-gene MG-GEM signature through LASSO Cox regression. The signature was validated for survival prediction and diagnostic performance using cross-validation and ROC analysis. Results The prognostic significance and predictive performance of the signature were validated in both internal and external cohorts, including this from the phase III PRODIGE-24/CCTG PA6 trial, composed of 167 GEM and 183 FOLFIRINOX (mFFX) patients. Importantly, the MG-GEM signature demonstrated independent and complementary predictive value relative to GemPred. Conclusion We present a novel clinically actionable 16-gene transcriptomic signature reflecting MG-induced stress that enables robust stratification of PDAC patients likely to benefit from adjuvant GEM therapy. This model supports the development of personalized treatment strategies in pancreatic cancer. Key Objective Can metabolic gemcitabine (GEM) resistant inducer methylglyoxal stress be used to predict resistance to adjuvant GEM through a transcriptomic signature? Knowledge Generated The transcriptomic MG-GEM signature demonstrated the ability to distinguish between GEM sensitive and GEM resistant patients in the internal cohorts from Erasme University Hospital. MG-GEMs predictive capacity was further validated in the independent PRODIGE-24/CCTG PA6 clinical trial data. When compared to the established GemPred transcriptomic signature, MG-GEM exhibited an independent predictive behaviour. Moreover, combining both independent signatures enhanced the identification of GEM sensitive and GEM resistant patient subgroups. This combined approach may be particularly valuable in identifying patient subsets with treatment- specific responses.
Open AccessGlycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer
Purpose Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, largely due to chemoresistance arising from prominent cellular heterogeneity and a complex tumor microenvironment. Given this challenge, understanding the mechanisms of driving chemoresistance is essential for guiding our chemotherapeutic choice. Emerging evidence suggests that methylglyoxal (MG), a reactive glycolytic byproduct, may play a role in modulating tumor behavior and therapy response, offering a novel angle for patient stratification. Our recent study indicates that the accumulation of MG in PDAC cells leads to MG-induced cellular stress associated with gemcitabine (GEM) resistance. The primary objective of this study was to identify a predictive transcriptomic signature associated with MG stress in PDAC and compare it to the recently reported GemPred signature. Patients and methods MG stress classification was applied to the Puleo et al. cohort (n=309), enabling differential gene expression analysis and the development of a prognostic 16-gene MG-GEM signature through LASSO Cox regression. The signature was validated for survival prediction and diagnostic performance using cross-validation and ROC analysis. Results The prognostic significance and predictive performance of the signature were validated in both internal and external cohorts, including this from the phase III PRODIGE-24/CCTG PA6 trial, composed of 167 GEM and 183 FOLFIRINOX (mFFX) patients. Importantly, the MG-GEM signature demonstrated independent and complementary predictive value relative to GemPred. Conclusion We present a novel clinically actionable 16-gene transcriptomic signature reflecting MG-induced stress that enables robust stratification of PDAC patients likely to benefit from adjuvant GEM therapy. This model supports the development of personalized treatment strategies in pancreatic cancer. Key Objective Can metabolic gemcitabine (GEM) resistant inducer methylglyoxal stress be used to predict resistance to adjuvant GEM through a transcriptomic signature? Knowledge Generated The transcriptomic MG-GEM signature demonstrated the ability to distinguish between GEM sensitive and GEM resistant patients in the internal cohorts from Erasme University Hospital. MG-GEMs predictive capacity was further validated in the independent PRODIGE-24/CCTG PA6 clinical trial data. When compared to the established GemPred transcriptomic signature, MG-GEM exhibited an independent predictive behaviour. Moreover, combining both independent signatures enhanced the identification of GEM sensitive and GEM resistant patient subgroups. This combined approach may be particularly valuable in identifying patient subsets with treatment- specific responses.
- Open Access
Duodenal organoids from metabolic dysfunction-associated steatohepatitis patients exhibit altered digestive homeostasis
Background and Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Though MASH is closely tied to metabolic risk factors, the underlying pathogenic mechanisms remain scarcely understood. Recent research underscores the importance of the gut-liver axis in its pathogenesis, an aspect less explored in human studies. Here, we investigated whether the duodenal epithelium of MASH patients, could exhibit intrinsic dysfunctions. Methods Duodenal epithelial organoids were generated from 16 MASH patients and 14 healthy controls. Biopsies and patient-derived organoid transcriptomes were then analyzed to evaluate if specific intestinal pathways were differentially modulated in MASH subjects. Functional assays were performed to assess the duodenal epithelial digestive potential and barrier functionality. Results Organoid formation efficiency was similar between control-derived epithelial organoids (CDEOs) and MASH-derived epithelial organoids (MDEOs) (71% and 69%, respectively). Despite global heterogeneity in growth patterns, MDEOs frequently exhibited cystic spheroid morphology. MDEOs displayed altered digestive homeostasis associated with reduced mature absorptive cell fate, but they retained their lipid metabolic capacity, possibly mediated by lipid oxidation in stem/progenitor cells. Additionally, MDEOs misexpressed components of tight and adherens junctions and desmosomes compared to controls. However, MDEOs maintained pore and leak pathway integrity, indicating that the duodenal epithelial barrier remained functionally preserved under tested conditions. Conclusions This study provides evidence that the duodenal epithelium of MASH patients exhibits significant alterations in its digestive and barrier functions. This study sheds light on the intricate dynamics of duodenal epithelial alterations in MASH, highlighting potential therapeutic avenues for restoring intestinal homeostasis.
Open AccessDuodenal organoids from metabolic dysfunction-associated steatohepatitis patients exhibit altered digestive homeostasis
Background and Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Though MASH is closely tied to metabolic risk factors, the underlying pathogenic mechanisms remain scarcely understood. Recent research underscores the importance of the gut-liver axis in its pathogenesis, an aspect less explored in human studies. Here, we investigated whether the duodenal epithelium of MASH patients, could exhibit intrinsic dysfunctions. Methods Duodenal epithelial organoids were generated from 16 MASH patients and 14 healthy controls. Biopsies and patient-derived organoid transcriptomes were then analyzed to evaluate if specific intestinal pathways were differentially modulated in MASH subjects. Functional assays were performed to assess the duodenal epithelial digestive potential and barrier functionality. Results Organoid formation efficiency was similar between control-derived epithelial organoids (CDEOs) and MASH-derived epithelial organoids (MDEOs) (71% and 69%, respectively). Despite global heterogeneity in growth patterns, MDEOs frequently exhibited cystic spheroid morphology. MDEOs displayed altered digestive homeostasis associated with reduced mature absorptive cell fate, but they retained their lipid metabolic capacity, possibly mediated by lipid oxidation in stem/progenitor cells. Additionally, MDEOs misexpressed components of tight and adherens junctions and desmosomes compared to controls. However, MDEOs maintained pore and leak pathway integrity, indicating that the duodenal epithelial barrier remained functionally preserved under tested conditions. Conclusions This study provides evidence that the duodenal epithelium of MASH patients exhibits significant alterations in its digestive and barrier functions. This study sheds light on the intricate dynamics of duodenal epithelial alterations in MASH, highlighting potential therapeutic avenues for restoring intestinal homeostasis.
- Open Access
Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion of isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for the treatment of localized PDAC. However, the histo-molecular effects of iHD-SBRT are still poorly explored. In this study, we have shown that TNT, associating FOLFIRINOX [FFX] followed by iHD-SBRT, leads to significant and long-lasting remodeling of PDAC, affecting its stromal, metabolic, and molecular features. Contrary to FFX alone, TNT is able to enrich tumors with Classical and Inactive stromal signatures associated with better prognosis. Furthermore, iHD-SBRT seems capable to counteract several of the detrimental modulatory effects induced by FFX such as Epithelial-to-Mesenchymal Transition or angiogenesis. Additionally, we identified inflammatory cancer-associated fibroblasts signatures as an important prognostic factor. This work provides new rationale to sequentially combine FFX with iHD-SBRT and suggests new pathways that can be targeted in combination with a TNT.
Open AccessFavorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion of isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for the treatment of localized PDAC. However, the histo-molecular effects of iHD-SBRT are still poorly explored. In this study, we have shown that TNT, associating FOLFIRINOX [FFX] followed by iHD-SBRT, leads to significant and long-lasting remodeling of PDAC, affecting its stromal, metabolic, and molecular features. Contrary to FFX alone, TNT is able to enrich tumors with Classical and Inactive stromal signatures associated with better prognosis. Furthermore, iHD-SBRT seems capable to counteract several of the detrimental modulatory effects induced by FFX such as Epithelial-to-Mesenchymal Transition or angiogenesis. Additionally, we identified inflammatory cancer-associated fibroblasts signatures as an important prognostic factor. This work provides new rationale to sequentially combine FFX with iHD-SBRT and suggests new pathways that can be targeted in combination with a TNT.
- Open Access
- 6 July 2022
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2022, 1-3
Ovarian Clear Cell Carcinoma with Functioning Stroma and Associated Endometrial Intraepithelial Neoplasia
We report the case of a 79-year-old woman with a large pelvic mass and postmenopausal bleeding, associated with hyperestrogenism. A pelvic MRI shows the presence of a large mass of 12.6cm originating from the right ovary without signs of metastasis. A total abdominal hysterectomy with unilateral salpingooophorectomy was performed, knowing the patient underwent a left salpingooophorectomy decades ago. The pathological findings showed an ovarian clear cell carcinoma (pT1A) with associated endometrial intraepithelial neoplasia. There is convincing evidence that the production of estrogen is located in the activated ovarian stroma. This supports the view that functioning stroma of ovarian cancer can lead to hyperestrogenism and eventually endometrial cancer.
- 6 July 2022
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2022, 1-3
Open AccessOvarian Clear Cell Carcinoma with Functioning Stroma and Associated Endometrial Intraepithelial Neoplasia
We report the case of a 79-year-old woman with a large pelvic mass and postmenopausal bleeding, associated with hyperestrogenism. A pelvic MRI shows the presence of a large mass of 12.6cm originating from the right ovary without signs of metastasis. A total abdominal hysterectomy with unilateral salpingooophorectomy was performed, knowing the patient underwent a left salpingooophorectomy decades ago. The pathological findings showed an ovarian clear cell carcinoma (pT1A) with associated endometrial intraepithelial neoplasia. There is convincing evidence that the production of estrogen is located in the activated ovarian stroma. This supports the view that functioning stroma of ovarian cancer can lead to hyperestrogenism and eventually endometrial cancer.
- Open Access
- 13 June 2022
- Published by Hindawi Limited in Case Reports in Pathology
- Vol. 2022, 1-5
Ectopic Fetal Liver Tissue in the Placenta of a Twin Pregnancy: A Case Report and Review of Literature
Ectopic liver tissue represents a rare entity and is mostly attributed to events occurring during embryogenesis. Previous case reports documented the presence of fetal liver parenchyma within temporarily developed organs during pregnancy, such as the placenta or the umbilical cord. Moreover, the terminology of these benign findings varies from ectopic liver to hepatocellular adenoma-like neoplasm or hepatocellular adenoma. Ancillary tests performed on these lesions have shown positive immunohistochemical staining for hepatocellular origin marker HepPar-1. Only one recent case report comprising molecular analysis showed no beta-catenin gain-of-function mutation. We report a case of ectopic liver in one placenta of a twin pregnancy, with an updated review of literature.
- 13 June 2022
- Published by Hindawi Limited in Case Reports in Pathology
- Vol. 2022, 1-5
Open AccessEctopic Fetal Liver Tissue in the Placenta of a Twin Pregnancy: A Case Report and Review of Literature
Ectopic liver tissue represents a rare entity and is mostly attributed to events occurring during embryogenesis. Previous case reports documented the presence of fetal liver parenchyma within temporarily developed organs during pregnancy, such as the placenta or the umbilical cord. Moreover, the terminology of these benign findings varies from ectopic liver to hepatocellular adenoma-like neoplasm or hepatocellular adenoma. Ancillary tests performed on these lesions have shown positive immunohistochemical staining for hepatocellular origin marker HepPar-1. Only one recent case report comprising molecular analysis showed no beta-catenin gain-of-function mutation. We report a case of ectopic liver in one placenta of a twin pregnancy, with an updated review of literature.
- Open Access
- 1 June 2022
- Published by Universa BV in Acta Gastro Enterologica Belgica
- Vol. 85 (2) , 396-399
Immature squamous metaplasia of esophageal glands associated with squamous cell carcinoma
Background: Esophageal immature squamous metaplasia is hardly reported in the literature. This entity can, however, be misinterpreted as high grade dysplasia or invasive squamous cell carcinoma and hence represent a potential pitfall. Case presentation: Histopathological examination of a superficial esophageal lesion removed by endoscopic submucosal dissection revealed a squamous cell carcinoma associated with immature squamous cell metaplasia arising from esophageal glands. Immunohistochemical stainings allowed to distinguish malignant from metaplastic cells. Conclusions: Immunohistochemistry for Ber-EP4 is helpful in making the distinction between esophageal squamous cell carcinoma and immature squamous metaplasia. This can avoid overstaging and overtreatment, especially in early esophageal cancer.
- 1 June 2022
- Published by Universa BV in Acta Gastro Enterologica Belgica
- Vol. 85 (2) , 396-399
Open AccessImmature squamous metaplasia of esophageal glands associated with squamous cell carcinoma
Background: Esophageal immature squamous metaplasia is hardly reported in the literature. This entity can, however, be misinterpreted as high grade dysplasia or invasive squamous cell carcinoma and hence represent a potential pitfall. Case presentation: Histopathological examination of a superficial esophageal lesion removed by endoscopic submucosal dissection revealed a squamous cell carcinoma associated with immature squamous cell metaplasia arising from esophageal glands. Immunohistochemical stainings allowed to distinguish malignant from metaplastic cells. Conclusions: Immunohistochemistry for Ber-EP4 is helpful in making the distinction between esophageal squamous cell carcinoma and immature squamous metaplasia. This can avoid overstaging and overtreatment, especially in early esophageal cancer.
- 14 April 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 01) , S8-S9
MID GUT EXPLORATION: CAN CAPSULE ENDOSCOPY ALWAYS DETERMINE THE INSERTION ROUTE OF DEVICE-ASSISTED ENTEROSCOPY?
Small bowel capsule endoscopy (SBCE) is a well-known non-invasive technique that has revolutionized the exploration of the midgut as device-assisted enteroscopy (DAE) development. Both procedures are complementary and SBCE can be considered a previous guide before a deep enteroscopy procedure that requires expertise, time and general anesthesia. Which route of insertion (anterograde or retrograde) should be chosen, isn’t simple. Few studies have tried to identify a time index based on SBCE landmarks to help the decision of the route insertion. We illustrated two video cases where those formulas could not determine the correct approach before motorized spiral enteroscopy. Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 01) , S8-S9
MID GUT EXPLORATION: CAN CAPSULE ENDOSCOPY ALWAYS DETERMINE THE INSERTION ROUTE OF DEVICE-ASSISTED ENTEROSCOPY?
Small bowel capsule endoscopy (SBCE) is a well-known non-invasive technique that has revolutionized the exploration of the midgut as device-assisted enteroscopy (DAE) development. Both procedures are complementary and SBCE can be considered a previous guide before a deep enteroscopy procedure that requires expertise, time and general anesthesia. Which route of insertion (anterograde or retrograde) should be chosen, isn’t simple. Few studies have tried to identify a time index based on SBCE landmarks to help the decision of the route insertion. We illustrated two video cases where those formulas could not determine the correct approach before motorized spiral enteroscopy. Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 01) , S196-S197
LARGE SUPERFICIAL SQUAMOUS CELL CARCINOMA IN THE SETTING OF ACHALASIA TREATED BY ENDOSCOPIC SUBMUCOSAL DISSECTION: PARTICULAR FEATURES OF SUPERFICIAL CARCINOMA ON STASIS RELATED ESOPHAGEAL HYPERKERATOSIS
Aims Methods Results A 69-years-old man presented dysphagia and weight loss for several years was referred after the discovery of a 6mm lesion with high-grade dysplasia. Abdominal computed tomography demonstrated stasis and wall thickening of the distal esophagus. High resolution manometry disclosed absent esophageal peristaltism but lower esophageal sphincter acceptable relaxation. Endoscopy revealed in the lower two thirds of the esophagus a keratinized mucosa caused by food stasis in the context of achalasia. A large flat (O-IIb) suspicious squamous dysplastic lesion was observed on 50% circumference from 30 to 40cm of the incisors. Examination using magnified narrow-band imaging and the near focus revealed Type B2 intrapapillary capillary loops in favor of mucosal lesion. Lugol chromoendoscopy confirmed the delineation of the lesion and its suspicious feature. En-bloc endoscopic resection using ESD was performed from 29 to 40cm of the incisors up to 60% of the circumference. Stricture prevention with in loco triamcilonone injection was offered associated to proton pump inhibitors treatment. The histopathological analysis of the 118x95mm resected specimen revealed a squamous cell carcinoma in situ of 100mm with a focal 9mm site of malignancy (pT1am3 moderately differentiated squamous cell carcinoma without lymphovascular or perineural invasion, no tumor budding). Vertical and lateral margins were free.The resection was curative. Endoscopic follow-up showed complete healing of the ESD scar without stricture or signs of recurrence. Dysphagia and weight loss resolved in the meanwhile. The particularity of this case is the feature of large superficial SCC in the setting of stasis and keratinized esophagus associated to achalasia. Conclusions: Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 01) , S196-S197
LARGE SUPERFICIAL SQUAMOUS CELL CARCINOMA IN THE SETTING OF ACHALASIA TREATED BY ENDOSCOPIC SUBMUCOSAL DISSECTION: PARTICULAR FEATURES OF SUPERFICIAL CARCINOMA ON STASIS RELATED ESOPHAGEAL HYPERKERATOSIS
Aims Methods Results A 69-years-old man presented dysphagia and weight loss for several years was referred after the discovery of a 6mm lesion with high-grade dysplasia. Abdominal computed tomography demonstrated stasis and wall thickening of the distal esophagus. High resolution manometry disclosed absent esophageal peristaltism but lower esophageal sphincter acceptable relaxation. Endoscopy revealed in the lower two thirds of the esophagus a keratinized mucosa caused by food stasis in the context of achalasia. A large flat (O-IIb) suspicious squamous dysplastic lesion was observed on 50% circumference from 30 to 40cm of the incisors. Examination using magnified narrow-band imaging and the near focus revealed Type B2 intrapapillary capillary loops in favor of mucosal lesion. Lugol chromoendoscopy confirmed the delineation of the lesion and its suspicious feature. En-bloc endoscopic resection using ESD was performed from 29 to 40cm of the incisors up to 60% of the circumference. Stricture prevention with in loco triamcilonone injection was offered associated to proton pump inhibitors treatment. The histopathological analysis of the 118x95mm resected specimen revealed a squamous cell carcinoma in situ of 100mm with a focal 9mm site of malignancy (pT1am3 moderately differentiated squamous cell carcinoma without lymphovascular or perineural invasion, no tumor budding). Vertical and lateral margins were free.The resection was curative. Endoscopic follow-up showed complete healing of the ESD scar without stricture or signs of recurrence. Dysphagia and weight loss resolved in the meanwhile. The particularity of this case is the feature of large superficial SCC in the setting of stasis and keratinized esophagus associated to achalasia. Conclusions: Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer
Although the overall survival rate of papillary or follicular thyroid cancers is good, anaplastic carcinomas and radio iodine refractory cancers remain a significant therapeutic challenge. Galectin-1 (Gal-1) is overexpressed in tumor cells and tumor-associated endothelial cells, and is broadly implicated in angiogenesis, cancer cell motility and invasion, and immune system escape. Our team has previously demonstrated a higher serum level of Gal-1 in patients with differentiated thyroid cancers versus healthy patients, and explored, by a knockdown strategy, the effect of Gal-1 silencing on cell proliferation and invasion in vitro, and on tumor and metastasis development in vivo. OTX008 is a calixarene derivative designed to bind the Gal-1 amphipathic β-sheet conformation and has previously demonstrated anti-proliferative and anti-invasive properties in several cancer cell lines including colon, breast, head and neck, and prostate cancer lines. In the current work, the impacts of OTX008 were evaluated in six thyroid cancer cell lines, and significant inhibitions of proliferation, migration, and invasion were observed in all lines expressing high Gal-1 levels. In addition, the signaling pathways affected by this drug were examined using RPPA (reverse phase protein array) and phosphoprotein expression assays, and opposite regulation of eNos, PYK2, and HSP27 by OTX008 was detected by comparing the two anaplastic lines 8505c and CAL 62. Finally, the sensitive 8505c line was xenografted in nude mice, and 3 weeks of OTX008 treatment (5 mg/kg/day) demonstrated a significant reduction in tumor and lung metastasize sizes without side effects. Overall, OXT008 showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1, supporting further investigation of the molecular mechanisms of the drug and future clinical trials in patients with anaplastic thyroid cancer.
Open AccessNew Treatment Strategy Targeting Galectin-1 against Thyroid Cancer
Although the overall survival rate of papillary or follicular thyroid cancers is good, anaplastic carcinomas and radio iodine refractory cancers remain a significant therapeutic challenge. Galectin-1 (Gal-1) is overexpressed in tumor cells and tumor-associated endothelial cells, and is broadly implicated in angiogenesis, cancer cell motility and invasion, and immune system escape. Our team has previously demonstrated a higher serum level of Gal-1 in patients with differentiated thyroid cancers versus healthy patients, and explored, by a knockdown strategy, the effect of Gal-1 silencing on cell proliferation and invasion in vitro, and on tumor and metastasis development in vivo. OTX008 is a calixarene derivative designed to bind the Gal-1 amphipathic β-sheet conformation and has previously demonstrated anti-proliferative and anti-invasive properties in several cancer cell lines including colon, breast, head and neck, and prostate cancer lines. In the current work, the impacts of OTX008 were evaluated in six thyroid cancer cell lines, and significant inhibitions of proliferation, migration, and invasion were observed in all lines expressing high Gal-1 levels. In addition, the signaling pathways affected by this drug were examined using RPPA (reverse phase protein array) and phosphoprotein expression assays, and opposite regulation of eNos, PYK2, and HSP27 by OTX008 was detected by comparing the two anaplastic lines 8505c and CAL 62. Finally, the sensitive 8505c line was xenografted in nude mice, and 3 weeks of OTX008 treatment (5 mg/kg/day) demonstrated a significant reduction in tumor and lung metastasize sizes without side effects. Overall, OXT008 showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1, supporting further investigation of the molecular mechanisms of the drug and future clinical trials in patients with anaplastic thyroid cancer.
- Open Access
ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection
The coronavirus pandemic raging worldwide since December 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which invades human cells via the angiotensin-converting enzyme 2 (ACE2) receptor. Although it has already been identified in many organs, ACE2 expression remains largely unknown in the head and neck (HN) sphere. Thus, this study aims to investigate its protein expression in several sites of the upper aerodigestive tract in order to highlight potential routes of infection. We compared ACE2 immunohistochemical expression between 70 paraffin-embedded specimens with two different antibodies and reported the quantified expression in each histological location. Surprisingly, we obtained different results depending on the antibody, an absence of labeling having been observed with a monoclonal antibody raised against the extracellular domain, whereas the polyclonal, against the cytoplasmic part of the protein, revealed enriched ACE2 expression, particularly in sinuses, vocal cords, salivary glands and oral cavity epithelial cells. The interpretation of these discordant results has brought several exciting lines of reflection. In conclusion, this study provides possible routes of entry for the SARS-CoV-2 in HN region and, above all, has led us to encourage caution when studying the ACE2 expression which is currently at the center of all attention.
Open AccessACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection
The coronavirus pandemic raging worldwide since December 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which invades human cells via the angiotensin-converting enzyme 2 (ACE2) receptor. Although it has already been identified in many organs, ACE2 expression remains largely unknown in the head and neck (HN) sphere. Thus, this study aims to investigate its protein expression in several sites of the upper aerodigestive tract in order to highlight potential routes of infection. We compared ACE2 immunohistochemical expression between 70 paraffin-embedded specimens with two different antibodies and reported the quantified expression in each histological location. Surprisingly, we obtained different results depending on the antibody, an absence of labeling having been observed with a monoclonal antibody raised against the extracellular domain, whereas the polyclonal, against the cytoplasmic part of the protein, revealed enriched ACE2 expression, particularly in sinuses, vocal cords, salivary glands and oral cavity epithelial cells. The interpretation of these discordant results has brought several exciting lines of reflection. In conclusion, this study provides possible routes of entry for the SARS-CoV-2 in HN region and, above all, has led us to encourage caution when studying the ACE2 expression which is currently at the center of all attention.